Literature DB >> 10403829

Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.

R Asslan1, A Pradines, C Pratx, C Allal, G Favre, F Le Gaillard.   

Abstract

HMG-CoA reductase is the key enzyme for the biosynthesis of isoprenoid compounds essential for cell growth and differentiation. Its tyrosine kinase-dependent modulation has recently been suggested and described in the ErbB-2 overexpressing cell line SKBR-3 [Asslan et al. (1998) Biochem. J. 330, 241-246]. Epidermal growth factor (EGF) increased the HMG-CoA reductase activity, protein, and mRNA levels only in ErbB-2-expressing cells (SKBR-3 and MCF-7) but not in MDA-MB-468 cells that do not express ErbB-2 even though their EGF receptor was efficiently phosphorylated. Tyrphostin AG 879, a specific inhibitor of ErbB-2 tyrosine kinase activity, decreased HMG-CoA reductase activity only in cells that expressed ErbB-2. A functional EGF receptor appeared to be necessary since its inhibition by the specific tyrphostin AG 1478 abolished the EGF effects. Phosphatidylinositol 3-kinase (PI 3-kinase) might be a crucial enzyme in the signaling pathway since the specific inhibitor, LY 294002, was shown to inhibit HMG-CoA reductase activity and to completely abolish the stimulation by EGF in SKBR-3 cells. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10403829     DOI: 10.1006/bbrc.1999.0945

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer.

Authors:  Vidyalakshmi Sethunath; Huizhong Hu; Carmine De Angelis; Jamunarani Veeraraghavan; Lanfang Qin; Nicholas Wang; Lukas M Simon; Tao Wang; Xiaoyong Fu; Agostina Nardone; Resel Pereira; Sarmistha Nanda; Obi L Griffith; Anna Tsimelzon; Chad Shaw; Gary C Chamness; Jorge S Reis-Filho; Britta Weigelt; Laura M Heiser; Susan G Hilsenbeck; Shixia Huang; Mothaffar F Rimawi; Joe W Gray; C Kent Osborne; Rachel Schiff
Journal:  Mol Cancer Res       Date:  2019-08-16       Impact factor: 5.852

2.  Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.

Authors:  Jonathan Fisher; Pierre Abramowski; Nisansala Dilrukshi Wisidagamage Don; Barry Flutter; Anna Capsomidis; Gordon Weng-Kit Cheung; Kenth Gustafsson; John Anderson
Journal:  Mol Ther       Date:  2017-03-22       Impact factor: 11.454

Review 3.  The interplay between cell signalling and the mevalonate pathway in cancer.

Authors:  Peter J Mullen; Rosemary Yu; Joseph Longo; Michael C Archer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2016-08-26       Impact factor: 60.716

4.  Anti-tumor cytotoxicity of gammadelta T cells expanded from peripheral blood cells of patients with myeloma and lymphoma.

Authors:  Anri Saitoh; Miwako Narita; Norihiro Watanabe; Nozomi Tochiki; Noriyuki Satoh; Jun Takizawa; Tatsuo Furukawa; Ken Toba; Yoshifusa Aizawa; Shohji Shinada; Masuhiro Takahashi
Journal:  Med Oncol       Date:  2007-09-11       Impact factor: 3.064

5.  Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors.

Authors:  Jonathan Fisher; Roshan Sharma; Dilu Wisidagamage Don; Marta Barisa; Marina Olle Hurtado; Pierre Abramowski; Lucy Porter; William Day; Roberto Borea; Sarah Inglott; John Anderson; Dana Pe'er
Journal:  Sci Signal       Date:  2019-09-10       Impact factor: 8.192

Review 6.  Sensing of Pyrophosphate Metabolites by Vγ9Vδ2 T Cells.

Authors:  Siyi Gu; Wioletta Nawrocka; Erin J Adams
Journal:  Front Immunol       Date:  2015-01-22       Impact factor: 7.561

Review 7.  Towards Deciphering the Hidden Mechanisms That Contribute to the Antigenic Activation Process of Human Vγ9Vδ2 T Cells.

Authors:  Lola Boutin; Emmanuel Scotet
Journal:  Front Immunol       Date:  2018-04-20       Impact factor: 7.561

8.  Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells.

Authors:  Hans-Jürgen Gober; Magdalena Kistowska; Lena Angman; Paul Jenö; Lucia Mori; Gennaro De Libero
Journal:  J Exp Med       Date:  2003-01-20       Impact factor: 14.307

Review 9.  Engineering Approaches in Human Gamma Delta T Cells for Cancer Immunotherapy.

Authors:  Jonathan Fisher; John Anderson
Journal:  Front Immunol       Date:  2018-06-26       Impact factor: 7.561

10.  A Retrospective Hospital-Based Study of HMGCR Expression in HER2 IHC 2+ and 3+ Breast Cancer.

Authors:  Malisalaora Mohamed; Siti Norasikin Mohd Nafi; Hasnan Jaafar; Noorasmaliza Md Paiman
Journal:  Asian Pac J Cancer Prev       Date:  2021-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.